Adipotide
preclinicalAlso known as: FTPP, Prohibitin-TP01
**Mechanism of Action** Adipotide (FTPP, Prohibitin-TP01) is a proapoptotic peptidomimetic that selectively targets prohibitin, a protein overexpressed on the surface of endothelial cells in white adipose tissue (WAT) vasculature. By binding to prohibitin, Adipotide triggers apoptosis in these endothelial cells, leading to the destruction of the blood supply feeding WAT. This results in localized fat reduction through ischemic necrosis and subsequent clearance of dead adipocytes. **Key Research Findings** Preclinical studies in non-human primates demonstrated that systemic administration of Adipotide induced significant, dose-dependent reductions in body weight and fat mass, particularly in visceral adipose depots. The treatment also improved metabolic parameters, including fasting glucose and insulin sensitivity. However, reversible renal tubular injury was observed as a side effect, likely due to prohibitin expression in kidney vasculature. Only three PubMed-indexed studies exist, all in preclinical models. **Clinical Relevance** Adipotide remains in preclinical development with no human trials conducted to date. Its potential application is for obesity treatment, particularly targeting metabolically harmful visceral fat. The renal toxicity profile and lack of human safety data limit its translational progress. Further research is needed to optimize selectivity and mitigate off-target effects. For research purposes only — not medical advice.
Key data
C111H206N36O28S2Research & studies
KLA-PTNP reduced body weight and serum leptin levels in DIO mice, unlike the bioconjugate Adipotide.; KLA-PTNP decreased ectopic fat deposits in liver and muscle with elevated serum adiponectin and no hepatotoxicity.; PTNP delivery was enhanced by the EPR effect and multivalent active targeting, enabling cytoplasmic delivery into adipose endothelial cells.
Adipotide's weight loss effect may stem from decreased food consumption.; The original study's mechanism of vascular apoptosis is questioned.; Obese monkeys showed improved insulin resistance, but cause is debated.
Adipotide induced targeted apoptosis in white adipose tissue blood vessels.; Treatment resulted in rapid weight loss and improved insulin resistance in obese monkeys.; MRI and dual-energy x-ray absorptiometry confirmed marked reduction in white adipose tissue.; Optimal doses caused predictable and reversible changes in renal proximal tubule function.
Frequently asked questions
What is Adipotide?
**Mechanism of Action** Adipotide (FTPP, Prohibitin-TP01) is a proapoptotic peptidomimetic that selectively targets prohibitin, a protein overexpressed on the surface of endothelial cells in white adipose tissue (WAT) vasculature. By binding to prohibitin, Adipotide triggers apoptosis in these endothelial cells, leadin
How does Adipotide work?
Proapoptotic peptidomimetic that targets the blood supply of white adipose tissue, causing fat reduction in primate studies.
What is the research status of Adipotide?
Adipotide is currently classified as preclinical, with 3 research references on record. This is for research purposes only and is not medical advice.
What is the molecular weight of Adipotide?
Adipotide has a molecular weight of approximately 2557.2 g/mol (formula C111H206N36O28S2).
Related peptides
Once-daily acylated GLP-1 receptor agonist for type 2 diabetes and chronic weight management.
Long-acting GLP-1 receptor agonist that improves glycemic control, slows gastric emptying, and reduces appetite.
Exendin-4-based GLP-1 receptor agonist from Gila monster venom; first-in-class incretin mimetic.
Dual GIP/GLP-1 receptor agonist delivering potent glucose lowering and weight reduction.
Once-weekly GLP-1 receptor agonist fused to an IgG4 Fc fragment for extended half-life.
Short-acting exendin-4-based GLP-1 receptor agonist with pronounced gastric-emptying delay.
Build on Adipotide data programmatically
Structured peptide data, semantic search, and AI summaries via one API.
Get a free API key